Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug is expensive, and many people can't get it yet.

The first new non-opioid for severe acute pain has been on the market for a few months. But it's a lot more expensive than opioids, and many people can't get it because of spotty insurance coverage.

Novavax Inc. closed 60.47% below its 52-week high of $17.81, which the company achieved on July 26th.

The stock's fall snapped a three-day winning streak.

The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...

The study revealed that recipients of NUVAXOVID showed fewer and less severe systemic side effects, with just 24.2% having symptoms of Grade 2 severity or higher.

Novavax (NasdaqGS:NVAX) recently announced preliminary results from its SHIELD-Utah study, showcasing the Novavax COVID-19 vaccine's effectiveness and reduced side effects compared to a competitor ...

Novavax says its COVID-19 vaccine BLA is approvable and awaits FDA response after a post-marketing data request. SHIELD-Utah study shows Novavax’s JN.1 vaccine had milder side effects than ...